EGFR modulates complement activation in head and neck squamous cell carcinoma

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Epidermal growth factor receptor (EGFR) is crucial for epithelial cell growth and is overexpressed in cancers like head and neck squamous cell carcinoma (HNSCC).
• EGFR signaling impacts innate immune functions in epithelia, with a known role in modulating the complement system in skin.

Purpose of the Study:

• To investigate the role of EGFR in modulating the complement system specifically within HNSCC.
• To understand how EGFR inhibition affects complement activation in HNSCC.

Main Methods:

• Utilized patient-derived HNSCC cell lines with varying sensitivities to EGFR inhibitors.
• Generated EGFR inhibition-resistant HNSCC cell lines for comparative analysis.

Main Results:

• HNSCC cell lines activate the complement system upon incubation with human serum.
• Complement activation increased in EGFR inhibitor-sensitive cell lines treated with the tyrosine kinase inhibitor Iressa.
• EGFR-inhibitor resistant cell lines showed complement activation and reduced complement regulatory proteins, even without inhibitors.
• Complement activation did not lead to HNSCC cell lysis but increased extracellular signal-regulated kinase (ERK) phosphorylation in one cell line.

Conclusions:

• EGFR plays a significant role in modulating the complement system in HNSCC.
• Prolonged EGFR inhibition in sensitive HNSCC cells enhances complement activation.
• Findings have implications for understanding EGFR inhibitor efficacy, resistance mechanisms, and inflammatory side effects like skin lesions, which often lead to treatment discontinuation.